Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents

Conditions

• Depression
• Depression in Adolescence
• Major Depressive Disorder
• Major Depressive Episode

Eligibility Criteria

Sex

ALL

Age

13 Years - 20 Years

Healthy Volunteers

Not accepted

Interventions

• MagPro X100 edition (MagVenture, Skovlunde, Denmark) — DEVICE
  10 daily sessions (50 total over 5-days) of aiTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
• MagPro X100 edition (MagVenture, Skovlunde, Denmark) — DEVICE
  5 daily sessions (25 total over 5-days) of aiTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).

Study Details

This is a single-site open-label clinical trial of fMRI-guided accelerated intermittent theta burst stimulation. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS)-is effective as a first-line therapy in treating adolescents aged 13-20 years-old in their first episode of depression who have not undergone a full course of depression treatment prior to starting the trial and who remain antidepressant-free throughout the trial. The main questions this trial aims to answer are: * Does aiTBS relieve symptoms of depression as a first-line therapy in adolescents? * Is aiTBS a feasible option as a first-line treatment for adolescent depression? Researchers will measure the depression symptoms in adolescent participants before and after aiTBS. Parents of the adolescent participant will also participate in the study providing information about their experience and preference for TMS as a first-line treatment. Adolescent participants will: * Remain antidepressant-free throughout the study period of 6-7 weeks. * Receive an fMRI of their head for precision targeting * Receive 5 days of aiTBS

Key Dates

First listed

Jul 26, 2024

Start date

Apr 1, 2025

Status verified

Apr 2026

Primary completion

Sep 30, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

40 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Full-Dose paiTBS
  10 daily sessions (50 total over 5-days) of paiTBS stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
• Experimental: Half-Dose paiTBS
  5 daily sessions (25 total over 5-days) of paiTBS stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).

Primary Outcome Measure

Childhood Depression Rating Scale-Revised (CDRS-R) Remission Rates [ Time Frame: Baseline, One Month Follow Up Visit ]

Central Contacts

• Daniella Santos
  512-495-5566
  [email protected]

Locations (1)

Find similar trials in Austin, TX

Related Studies

• DBS for Depression
  Recruiting · Baylor College of Medicine · Dallas, Texas
• Youth Depression and Suicide Research Network
  Enrolling By Invitation · University of Texas Southwestern Medical Center · Dallas, Texas
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  PHASE3 · Recruiting · AbbVie · Anaheim, California
• To Improve Depressive Symptoms Using a Web-App
  Recruiting · University of Texas at Austin · Austin, Texas